Cyproterone Acetate and Risk of Meningioma: A Nationwide Cohort Study

    June 2021 in “ Journal of neurology, neurosurgery and psychiatry ”
    A. B. Mikkelsen, Iben Katinka Greiber, Nikolai Madrid Scheller, Malene Hilden, Øjvind Lidegaard
    New to Cyproterone? There is a guide in the encyclopedia. Read the guide →
    Studysummary This study found that females exposed to high cumulative doses of cyproterone acetate had a 6–20 fold increased risk of developing meningiomas compared to those on lower doses. Our plain-language summary of this paper — not a Tressless recommendation.
    This nationwide cohort study investigated the association between cyproterone acetate (CPA) use and the risk of meningioma in Denmark. The study included individuals born between 1930 and 2000, followed from age 15 or later until 2017. The findings indicated that high cumulative doses of CPA significantly increased the risk of meningioma, with a 6-20 fold higher risk compared to low doses. This led to the European Medicines Agency recommending a restriction of CPA to less than 10 mg per day. The study underscores the importance of monitoring CPA dosage to mitigate the risk of meningioma.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results